Clinical Trials

SIG-001 is a candidate product for patients with severe or moderately severe hemophilia A (Factor VIII level 2% or less).

Sigilon plans to initiate a Phase 1/2 study in patients with severe or moderately severe hemophilia A in 2020. The study will evaluate the safety, tolerability, and efficacy of SIG-001 in adult male patients with severe or moderately severe hemophilia A without inhibitors.